机构:[1]Department of Neurosurgery, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China[2]Department of Neurosurgery, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.[3]Modern Medical Research Center, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China[4]Department of Endocrinology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Glioma is the most common type of primary malignant brain tumor in adults. Our previous work discovered that plasma miR-454-3p may have some advantages in glioma prognosis, but the clinical significance and the regulatory mechanism of miR-454-3p in glioma have not been systematically investigated, especially regarding the relationship between circulating and tissue miR-454-3p. The expression level of miR-454-3p in glioma serum and tissues was analyzed through quantitative real-time PCR (qRT-PCR). Cell-Counting Kit 8 (CCK-8), wound healing, transwell invasion, apoptosis, and immunofluorescence assays were used to assess the role of miR-454-3p in glioma cancer cells. ATG12 was selected as the target gene of miR-454-3p by bioinformatic analysis. The relationship between ATG12 and miR-454-3p was further validated by luciferase reporter assays and Western blot analysis. miR-454-3p was significantly downregulated in tumor tissues, while it was remarkably upregulated in exosomes from the same patients with glioma. The area under curve (AUC) of exosomal miR-454-3p for glioma diagnosis was 0.8663. The exosomal miR-454-3p was prominently lower in the postoperative serums than that in the preoperative serums. High miR-454-3p expression in exosomes or low miR-454-3p expression in tissue was associated with poor prognosis. Restored expression of miR-454-3p suppressed cell proliferation, migration, invasion, and autophagy in glioma. ATG12 was validated as a direct target of miR-454-3p. The overexpression of ATG12 could partially reverse the effects induced by miR-454-3p suppression. Our data indicate that miR-454-3p may serve as an exosomal biomarker and may be developed into a novel treatment for glioma.
基金:
This work was supported by the National Natural Science
Foundation of China (81302197) from Feng Zhi, Changzhou Science and Technology Support Program (CE20165048) from Feng Zhi, Changzhou High-
Level Medical Talents Training Project (2016CZBJ006) from Feng Zhi, and
Changzhou Municipal Commissions of Health and Family Planning Major
Scientific and Technological Project (ZD201620) from Naiyuan Shao
第一作者机构:[1]Department of Neurosurgery, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China[2]Department of Neurosurgery, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
通讯作者:
通讯机构:[*1]Third Affiliated Hospital of Soochow University, #185 Juqian Road, Changzhou, Jiangsu 213003, China[*2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, #1055 Sanxiang Road, Jiangsu, China
推荐引用方式(GB/T 7714):
Naiyuan Shao,Lian Xue,Rong Wang,et al.miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma[J].MOLECULAR CANCER THERAPEUTICS.2019,18(2):459-469.doi:10.1158/1535-7163.MCT-18-0725.
APA:
Naiyuan Shao,Lian Xue,Rong Wang,Kaiming Luo,Feng Zhi&Qing Lan.(2019).miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma.MOLECULAR CANCER THERAPEUTICS,18,(2)
MLA:
Naiyuan Shao,et al."miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma".MOLECULAR CANCER THERAPEUTICS 18..2(2019):459-469